8-K: Prestige Consumer Healthcare Reports Record Fiscal 2025 Revenue and Earnings

Prestige Consumer Healthcare Inc. announced record fiscal 2025 revenue of $1,137.8 million and diluted EPS of $4.29, with adjusted diluted EPS growing 7.4% year-over-year.

Summary

• Prestige Consumer Healthcare Inc. reported its financial results for the fourth quarter and fiscal year ended March 31, 2025.
• The company achieved record revenue of $296.5 million in Q4 and $1,137.8 million for fiscal year 2025.
• Organic revenue grew by 7.9% in Q4 and 1.2% in fiscal year 2025.
• Diluted EPS for fiscal year 2025 was $4.29, while adjusted diluted EPS was $4.52, a 7.4% increase year-over-year.
• The company reduced its leverage to 2.4x at year-end due to strong free cash flow and EBITDA growth.
• Prestige Consumer Healthcare anticipates fiscal 2026 organic revenue growth of approximately 1% to 2% and diluted EPS of $4.70 to $4.82.
• The company repurchased approximately 0.7 million shares at a total investment of approximately $51.5 million in fiscal 2025.
• The company expects approximately $15 million headwind related to the inflationary impacts of enacted tariffs to date.

Sentiment

Score: 7

Explanation: The document presents a positive outlook with record revenue and earnings, but acknowledges potential headwinds from tariffs and economic volatility. The company's strong free cash flow and disciplined capital allocation strategy contribute to a favorable sentiment.

Positives

• Record revenue achieved in fiscal year 2025.
• Strong growth in the International OTC Healthcare segment, led by the Hydralyte brand.
• Growth in the Gastrointestinal category.
• Reduction in leverage to 2.4x.
• Share repurchases of approximately $51.5 million.
• eCommerce channel growth accelerated in Q4.
• Gross margin expansion is projected for fiscal year 2026.
• The company anticipates approximately $1 billion total Free Cash Flow over the next four years.

Negatives

• The Cough & Cold category experienced declines.
• The company had a limited ability to supply strong demand for Clear Eyes.
• Net cash provided by operating activities for the fourth quarter of fiscal 2025 was $61.8 million compared to $66.9 million during the prior year comparable period.
• The company expects approximately $15 million headwind related to the inflationary impacts of enacted tariffs to date.

Risks

• The company anticipates an approximate $15 million headwind related to the inflationary impacts of enacted tariffs.
• The company faces a challenging and volatile macro operating environment.
• The company's ability to manage and mitigate inflationary costs is crucial to achieving its fiscal 2026 earnings outlook.
• The company's future operating results could be impacted by business and economic conditions, consumer trends, competitive pressures, and the ability of its manufacturing operations and third-party manufacturers to meet demand.

Future Outlook

Prestige Consumer Healthcare anticipates fiscal 2026 organic revenue growth of approximately 1% to 2% and diluted EPS of $4.70 to $4.82. The company projects free cash flow of $245 million or more for fiscal year 2026.

Management Comments

• We are very pleased with our fiscal year results, which delivered another year of consistent sales and earnings per share growth.
• The record fourth quarter sales performance exceeded our expectations, driven by continued International business strength, growth in a wide range of categories and brands in North America, and the success of the eCommerce channel thanks to our long-term investments and broad distribution.
• Execution of our proven strategy delivered a solid and steady performance in fiscal 2025.
• We believe our commitment to focused execution, a strong balance sheet, and the attributes of our diverse portfolio of needs-based products leaves us well positioned to continue generating consistent financial results and cash flow in this volatile backdrop, which should generate superior shareholder value creation.

Industry Context

Prestige Consumer Healthcare operates in the consumer healthcare products industry, which is characterized by stable demand for needs-based products. The company's focus on brand-building and diverse product portfolio positions it well to navigate the challenging and volatile macro operating environment.

Comparison to Industry Standards

• While a direct comparison to specific competitors isn't provided, Prestige's focus on over-the-counter (OTC) healthcare aligns with companies like Johnson & Johnson (Consumer Health division), Bayer (Consumer Health division), and Sanofi (Consumer Healthcare).
• Prestige's leverage ratio of 2.4x is generally considered healthy and provides financial flexibility compared to companies with higher debt levels.
• The projected organic revenue growth of 1-2% is a reasonable target in the mature consumer healthcare market, where growth is often driven by innovation and market share gains.

Stakeholder Impact

• Shareholders can expect continued value creation through consistent financial results and cash flow.
• Employees can expect a stable and growing company with opportunities for advancement.
• Customers can expect a continued focus on providing high-quality consumer healthcare products.

Next Steps

• The company will continue to focus on brand-building and leveraging its diverse portfolio.
• The company will pursue M&A opportunities and strategic share repurchases.
• The company will continue to deleverage to enhance optionality.
• The company will host a conference call to review its fourth quarter and fiscal 2025 results on May 8, 2025.

Key Dates

Keywords

revenue, earnings, EPS, organic growth, free cash flow, leverage, share repurchases, Prestige Consumer Healthcare, financial results